Perpetual Ltd Trims Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Perpetual Ltd lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 594,388 shares of the specialty pharmaceutical company’s stock after selling 81,043 shares during the period. Perpetual Ltd’s holdings in Jazz Pharmaceuticals were worth $73,199,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Lmcg Investments LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $5,599,000. MassMutual Private Wealth & Trust FSB grew its stake in Jazz Pharmaceuticals by 26,389.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 17,748 shares of the specialty pharmaceutical company’s stock worth $2,186,000 after purchasing an additional 17,681 shares in the last quarter. UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares in the last quarter. Ellsworth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after buying an additional 149 shares during the last quarter. Finally, Aaron Wealth Advisors LLC acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $301,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on JAZZ shares. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Trading Down 1.2 %

Shares of JAZZ stock opened at $121.18 on Tuesday. The firm has a market capitalization of $7.33 billion, a PE ratio of 17.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The stock has a fifty day moving average of $122.66 and a two-hundred day moving average of $114.87.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares in the company, valued at $51,742,619.25. This represents a 0.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,253 shares of company stock valued at $1,001,434 over the last 90 days. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.